DRUGs
China — biotech’s friend or foe?
America’s drug business is at a tipping point.
Fledgling startups and pharmaceutical giants alike are addicted to Chinese drugs, spending some $60 billion on Chinese molecules in the first three months of 2026 alone. Meanwhile, in the last decade, the U.S.’s share of the world’s medicine chest fell from nearly half to less than 35%. By pretty much any metric of biotech productivity, China has overtaken the U.S.
So, what should American companies do? Partner with Chinese companies? Or seal the borders and redirect all investment to homegrown efforts?
STAT’s Damian Garde has an excellent look at how China’s decades-long, state-sponsored push to insert its companies in the drug development pipeline is now forcing American biotech companies to make tough choices.
SCREENING
See a doc, save a prostate
Prostate-specific antigen blood testing — a procedure once thought to do more harm than good for prostate cancer — likely reduces the risk of deaths from the disease, according to a new review published Thursday.
The benefits are, admittedly, marginal. The Cochrane review analyzed results from six trials involving 800,000 participants and found that disease-specific death was reduced in about two every 1,000 men screened. But the study upends prior results that indicated the test did more harm than good, leading to overdiagnosis and overtreatment.
If you have a prostate and you’re reading this thinking that you need a PSA blood test ASAP to potentially save your life, I’d pump the brakes. It’s not that simple, as STAT’s Annalisa Merelli explains.
FDA
Marty Makary’s ally departs after his resignation
The fallout from Marty Makary’s resignation continues. Tracy Beth Høeg, head of the Food and Drug Administration’s drug center, is also leaving the agency after a rocky tenure.
Høeg, an epidemiologist and sports medicine physician, rose to prominence during the Covid-19 pandemic by challenging school closures, mask mandates, and the approval of booster shots for children. She continued to advocate for her vaccine views upon her start in April 2025 before later helming the agency’s Center for Drug Evaluation and Research. She quickly became involved with drug reviews during her tenure, a process typically handled by career scientists.
Read more about Høeg’s departure from STAT’s Lizzy Lawrence.